Key highlights
- 50% confirmed objective response rate in first-line casdatifan plus zimberelimab cohort
- 14.5-month median progression-free survival for second-line combination with cabozantinib
- 35-month median overall survival reported in late-line monotherapy pooled cohorts
- Primary progression rate of 6.7% observed in the first-line TKI-free combination group
- Safety profile remains consistent with previous studies across all evaluated treatment lines
What Happened
Arcus Biosciences presented comprehensive data from the ARC-20 platform study at an investor event on October 20, 2026. The study evaluated casdatifan, an oral HIF-2alpha inhibitor, as a potential treatment for clear cell renal cell carcinoma (ccRCC). Results spanned first-line TKI-free combinations, second-line treatments with cabozantinib, and late-line monotherapy. In the first-line setting, the combination of casdatifan and zimberelimab achieved a 50% confirmed objective response rate with 11.5 months of median follow-up. Progression-free survival landmarks reached 86% at six months and 69% at twelve months, with only 6.7% of patients experiencing primary progression at or before the first scan.
Significance
These findings suggest casdatifan may provide a durable response in ccRCC patients who have limited options or have progressed on previous tyrosine kinase inhibitor (TKI) therapies. In the second-line setting, the combination with cabozantinib yielded a 14.5-month median progression-free survival, notably maintaining efficacy regardless of whether patients had received prior TKI therapy. The late-line monotherapy data further reinforced the drug's activity, showing a median overall survival of 35 months. No unexpected safety signals were identified during the reporting period, with adverse events remaining manageable across the various dosing cohorts and treatment combinations evaluated in the ARC-20 study.
Business Overview
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing next-generation cancer therapies. The company pipeline centers on molecules targeting the adenosine pathway, CD73, and HIF-2alpha, often explored in combination with its proprietary anti-PD-1 antibody, zimberelimab. Arcus frequently collaborates with industry partners like Gilead Sciences and Summit Therapeutics to accelerate the development of its oncology portfolio. The company currently maintains its headquarters in Hayward, California, and operates several active clinical programs across various solid tumor types, including lung and kidney cancers, while exploring novel TKI-free combinations to improve patient outcomes.
Financial Context
Arcus Biosciences reported an annual revenue of $247 million for the previous fiscal year, with quarterly revenue reaching $41 million. As of mid-2026, the company held $775 million in cash, cash equivalents, and marketable securities. Management has guided that this capital is sufficient to fund operations through the second half of 2028. The stock currently trades with a 14-day Relative Strength Index (RSI) of 31.5, following a period of technical consolidation. The company anticipates total 2026 GAAP revenue between $65 million and $75 million, supported by ongoing clinical trial collaborations and milestone-based partnerships with larger pharmaceutical entities.
Down 23.8% since our story on 20 Oct: $22.14 when we broke it → $16.86 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $22.14 |
|---|---|
| 20 Oct | $23.75 |
| 21 Oct | $19.10 |
| 22 Oct | $19.36 |
| 23 Oct | $18.54 |
| 26 Oct | $17.76 |
| 27 Oct | $18.14 |
| 28 Oct | $18.39 |
| 29 Oct | $18.61 |
| 30 Oct | $18.19 |
| 2 Nov | $17.85 |
| 3 Nov | $18.91 |
| 4 Nov | $19.31 |
| 5 Nov | $17.69 |
| 6 Nov | $18.28 |
| 9 Nov | $18.95 |
| 10 Nov | $18.67 |
| 11 Nov | $18.80 |
| 12 Nov | $17.77 |
| 13 Nov | $17.43 |
| 16 Nov | $16.86 |
| Date | Announcement | Amount |
|---|---|---|
| 22 Sep 2026 | Announced investor event featuring new clinical data for casdatifan across multiple lines of therapy in kidney cancerSource: businesswire.com | – |
| 05 Aug 2026 | Reported second-quarter 2026 financial results and provided clinical pipeline updatesSource: businesswire.com | – |
| 22 Jul 2026 | Entered into a clinical trial collaboration with Summit Therapeutics to evaluate casdatifan combined with ivonescimabSource: investors.arcusbio.com | – |
| 03 Jun 2026 | Entered into clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate casdatifan with pumitamigSource: investors.arcusbio.com | – |
| 20 Apr 2026 | Discontinued Phase 3 STAR-121 study evaluating domvanalimab and zimberelimab in first-line metastatic NSCLC due to futilitySource: SEC filing | – |
| 30 Oct 2025 | Announced pricing of underwritten public offering of 13.7 million common shares at $18.25 per shareSource: investors.arcusbio.com | $250.0 Million |
| Share price | $22.14 |
|---|---|
| Market cap | $2.8B |
| Revenue (annual) | $247M |
| 1-month price change | -13.31% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Arcus Biosciences, Inc. announcing clinical data for casdatifan in clear cell renal cell carcinoma.
Track Arcus Biosciences, Inc. live
Get the next Arcus Biosciences, Inc. SEC filing seconds after it lands.
